Radiopharmaceuticals Market Report 2026

Radiopharmaceuticals Market Overview

• Radiopharmaceuticals market size has reached to $7.3 billion in 2025 • Expected to grow to $13.68 billion in 2030 at a compound annual growth rate (CAGR) of 13.5% • Growth Driver: Increasing Cancer And Cardiovascular Disease Prevalence Fuels Demand For Radiopharmaceuticals • Market Trend: Strategic Partnerships Drive Radiopharmaceutical Innovation And Accessibility • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Radiopharmaceuticals Market?

Radiopharmaceuticals refer to a medication used to treat or diagnose diseases, including cancer, that contains a radioactive material. Likewise known as radioactive medication. These are the procedures used to identify certain illnesses or detect medical issues. The patient may receive them in a number of different ways. They could be injected, injected orally, or injected into the eye or bladder, for instance. The main types of radiopharmaceuticals are diagnostic, therapeutic, and others. The delivery of radioactive atoms to tumor-associated targets is referred to as radiopharmaceutical therapeutic. The various applications include oncology, cardiology, gastroenterology, neuroendocrinology, neurology, nephrology, and others that are used by hospitals, ambulatory surgical centers, diagnostic centers, cancer research institutes, and others.

What Is The Radiopharmaceuticals Market Growth Forecast?

The radiopharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $13.68 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to growth in precision oncology, rising demand for targeted radiotherapies, expansion of diagnostic imaging centers, investments in cyclotron infrastructure, technological advancements in isotope production. Major trends in the forecast period include rising use of radiopharmaceuticals in oncology, growth of theranostics applications, expansion of pet and spect imaging, increasing development of targeted radiotherapies, improved nuclear medicine infrastructure.

Global Radiopharmaceuticals Market Segmentation

1) By Type: Diagnostic, Therapeutic 2) By Application: Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Musculoskeletal, Respiratory, Nephrology, Other Applications 3) By End User: Hospitals And Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes Subsegments: 1) By Diagnostic: Positron Emission Tomography (PET) Radiopharmaceuticals, Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals 2) By Therapeutic: Alpha Emitters, Beta Emitters, Brachytherapy

What Is The Driver Of The Radiopharmaceuticals Market?

The increasing prevalence of cancer and cardiovascular diseases is projected to drive the demand for the radiopharmaceuticals market. Radiopharmaceuticals are emerging as a safe and effective therapeutic option over conventional medicines. Radiopharmaceuticals provide an upper hand to radiologists to treat cancer and cardiovascular diseases due to their benefits such as targeted therapy. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. For instance, in April 2024, according to the International Agency for Research on Cancer (IARC), a France-based specialized agency, in 2022, nearly 20 million new cancer cases and 9.7 million cancer-related deaths occurred globally. By 2040, these numbers are projected to increase to 29.9 million new cases and 15.3 million deaths annually. Thus, the rising cases of cancer and cardiovascular diseases are expected to surge the demand for radiopharmaceuticals for the treatment of these diseases.

Key Players In The Global Radiopharmaceuticals Market

Major companies operating in the radiopharmaceuticals market are Cardinal Health, Curium Pharma, Siemens Healthineers AG, Novartis AG, General Electric Company (GE), IBA Group, Bayer AG, Lantheus Medical Imaging Inc., Bracco Imaging S.p.A., Eckert & Ziegler, Nihon Medi-Physics Co. Ltd., Fujifilm Corporation, ANSTO, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Bracco Imaging SpA., Canon Inc., China Isotope & Radiation Corporation (CIRC), Alliance Medical, Advanced Accelerator Applications, JSC Isotope, Pharm-Sintez, Synektik SA, Polatom, RadioMedic sro, ÚJV Řež, Actinium Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Avid Radiopharmaceuticals, Fusion Pharmaceuticals, Peregrine Pharmaceuticals Inc., PETNET Solutions Inc., Positron Corporation, Triad Isotopes Inc., Telix Pharmaceuticals, Rosatom, Alliance Medical Group, Hologic Inc., Segami Corporation, Eczacýbaþý-Monrol Nuclear Products, NTP Radioisotopes.

Global Radiopharmaceuticals Market Trends and Insights

Major companies operating in the radiopharmaceuticals market are increasingly forming strategic partnerships to accelerate innovation and expand access to advanced diagnostic and therapeutic solutions. These collaborations focus on enhancing radiopharmaceutical development, strengthening regional production capabilities, and supporting the growing demand for precision imaging and targeted therapies. For instance, in June 2023, the University of Pittsburgh Medical Center (UPMC), a US-based hospital system, partnered with PharmaLogic Holdings Corporation to co-develop and manufacture new radiopharmaceuticals at a Pittsburgh facility. The partnership aims to expand patient and clinician access to cutting-edge diagnostic and therapeutic agents that are not currently available in nearby regions. Under the non-exclusive agreement, UPMC and PharmaLogic will translate experimental radiopharmaceuticals into clinically useful medications, supporting broader commercialization and accelerating the adoption of novel nuclear medicine treatments.

What Are Latest Mergers And Acquisitions In The Radiopharmaceuticals Market?

In January 2024, Eli Lilly, a US-based pharmaceutical company, completed its acquisition of Point Biopharma for approximately $1.4 billion. This acquisition supports Lilly's strategy to enhance its capabilities in the emerging field of radioligand therapies, which aim to provide significant advancements in cancer treatment. Point Biopharma specializes in radiopharmaceuticals, aligning well with Lilly's existing oncology portfolio and promising to improve patient outcomes. Point Biopharma is a US-based company focused on developing targeted radioligand therapies for various cancers.

Regional Insights

North America was the largest region in the global radiopharmaceuticals market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Radiopharmaceuticals Market?

The radiopharmaceuticals market consists of sales of technetium disofenin, technetium lidofenin, and technetium mebrofenin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Radiopharmaceuticals Market Report 2026?

The radiopharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the radiopharmaceuticals industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.